These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31348619)

  • 1. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
    Parajuli S; Jug R; Ahmadi S; Jiang XS
    Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules.
    Jug R; Parajuli S; Ahmadi S; Jiang XS
    Endocr Pathol; 2019 Jun; 30(2):134-137. PubMed ID: 30825100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
    Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
    Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.
    Angell TE; Heller HT; Cibas ES; Barletta JA; Kim MI; Krane JF; Marqusee E
    Thyroid; 2019 May; 29(5):650-656. PubMed ID: 30803388
    [No Abstract]   [Full Text] [Related]  

  • 6. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 7. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
    Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
    J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
    McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
    Livhits MJ; Kuo EJ; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Zanocco KA; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2261-2268. PubMed ID: 29590358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology.
    Raghunathan R; Longstaff XR; Hughes EG; Li SJ; Sant VR; Tseng CH; Rao J; Wu JX; Yeh MW; Livhits MJ
    Surgery; 2024 Jan; 175(1):221-227. PubMed ID: 37926582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
    Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
    Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 15. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
    Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
    Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules.
    Wu JX; Young S; Hung ML; Li N; Yang SE; Cheung DS; Yeh MW; Livhits MJ
    Thyroid; 2016 Jul; 26(7):916-22. PubMed ID: 27161519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
    Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
    Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
    Wei S; Veloski C; Sharda P; Ehya H
    Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
    Yang Z; Zhang T; Layfield L; Esebua M
    J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.